Abu Dhabi Diabetes and Obesity Study

October 5, 2021 updated by: Dr Nader Lessan, MD, Imperial College London Diabetes Centre

Abu Dhabi Diabetes and Obesity Study (ADOS) - A Study on the Aetiology and Associated Risk Factors of Patients With Obesity/Diabetes Within the Emirati Population.

A cross-sectional study investigating the aetiology, mechanisms and associated complications contributing to obesity and diabetes within the UAE population. The study will be carried out in two main sample populations; children and adults, and characterized by the occurrence of obesity and diabetes. The main samples will then be divided into a subgroup for metabolomic analysis. Patients will be recruited from the Imperial College London Diabetes Centre. The study is aimed at elucidating the various factors that have an impact or may influence obesity and diabetes in the Emirati population.

Study Overview

Status

Completed

Conditions

Detailed Description

Obesity and Type 2 diabetes (T2DM) have been regarded as global epidemics in developed countries and more recently in developing nations. Obesity (a T2DM risk factor) and T2DM present significant health risks as individual diseases and substantial risks in individuals with both complications (Deepa Nath, 2006). The UAE and USA have a similar prevalence of obesity, 36% and 35.7% respectively. Interestingly, the percentage of the population with T2DM between the two groups differs significantly, 25% and 8.7% respectively. The rate of T2DM in the Emirati population is 2.9 fold higher than in the US. This suggests an altered inter relationship between obesity and T2DM. One hypothesis that could explain such a variation is differences in body metabolism and central adiposity between the two populations. This will be assessed by measuring cardiometabolic risk factors, central adiposity and metabolomics. Analysis of the metabolomic profiles may help define the risk factors associated with diabetes and differences in metabolic activity between various ethnicities.

Another area of ample interest is the advanced glycation end-products (AGEs) metabolic pathways (Pietropaoli D, 2012). AGEs are formed at an increased rate in diabetes and have a number of detrimental effects such as retinopathy, nephropathy and atherosclerosis (Melpomeni Peppa, 2003). As such, determining the core mechanisms that result in metabolic and cardiovascular dysfunction will aid in identifying and developing therapeutic targets, which may in turn alleviate the deleterious effects of respective disorders such as diabetes.

The aetiology of diabetes is complex. However, adenovirus 36 has been shown to play a significant role in obesity and diabetes. As such, analysis of ADV-36 occurrence within the Emirati population may provide insight into a novel obesity and diabetes risk factor and could further clarify the relationship between obesity and T2DM.

This study may provide evidence that clarifies how obesity can result in T2DM, and why this occurrence is more predominant in the Emirati population. In addition, the assessment of AGEs within the population, ranging from people with diabetes and obesity to healthy individual, may provide insight into potential therapeutic targets, thereby improving overall heath in the population. Finally, the data may improve our knowledge of new risk factors such as ADV-36 and their subsequent effects on diabetes.

Study Type

Observational

Enrollment (Anticipated)

2130

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Arab Emirates
      • Abu Dhabi, United Arab Emirates, 48338
        • Imperial College London Diabetes Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 years to 80 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients from the Imperial College London Diabetes Centre, Abu Dhabi.

Description

Inclusion Criteria:

  • All patients are eligible to participate in the study

Exclusion Criteria:

  • Under 5 years of age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Emirati Population

The individuals enrolled in this study will be divided into children (5-16 years of age) and adults (above 18). The groups will be further divided into BMI categories and glucose tolerance groups.

* Group 1: Underweight (adjusted BMI <10th percentile) and no diabetes

  • Group 2:

Normal weight (adjusted BMI 10th to 84.9th percentile) and no diabetes

  • Group 3:

Overweight or obese children (adjusted BMI >= 85th percentile) and no diabetes

  • Group 4:

Normal weight (adjusted BMI 10th to 84.9th percentile) and T1DM

  • Group 5:

Overweight or obese children (adjusted BMI ≥ 85th percentile) and T1DM

  • Group 6:

Normal weight (adjusted BMI 10th to 84.9th percentile) and T2DM

  • Group 7:

Overweight or obese children (adjusted BMI ≥ 85th percentile) and T2DM

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of the population in the U.A.E that are positive for adenovirus -36, specifically in children.
Time Frame: One year
The initial aim of the study is to measure the prevalence of adenovirus 36 in the Emirati population.
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Imperial College London Diabetes Centre

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2013

Primary Completion (Actual)

April 1, 2017

Study Completion (Actual)

April 1, 2017

Study Registration Dates

First Submitted

April 25, 2013

First Submitted That Met QC Criteria

April 30, 2013

First Posted (Estimate)

May 1, 2013

Study Record Updates

Last Update Posted (Actual)

October 13, 2021

Last Update Submitted That Met QC Criteria

October 5, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IREC008

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe